Chicago Partners Investment Group LLC purchased a new stake in shares of Incyte Corporation (NASDAQ:INCY - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 5,269 shares of the biopharmaceutical company's stock, valued at approximately $372,000.
A number of other large investors also recently bought and sold shares of INCY. AQR Capital Management LLC lifted its position in Incyte by 92.3% during the 1st quarter. AQR Capital Management LLC now owns 6,736,169 shares of the biopharmaceutical company's stock valued at $405,787,000 after acquiring an additional 3,233,356 shares during the period. Robeco Institutional Asset Management B.V. lifted its position in Incyte by 71.5% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 2,386,311 shares of the biopharmaceutical company's stock valued at $162,508,000 after acquiring an additional 995,204 shares during the period. Acadian Asset Management LLC lifted its position in Incyte by 65.6% during the 1st quarter. Acadian Asset Management LLC now owns 2,511,872 shares of the biopharmaceutical company's stock valued at $152,062,000 after acquiring an additional 994,609 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Incyte during the 2nd quarter valued at about $50,076,000. Finally, Victory Capital Management Inc. lifted its position in Incyte by 581.3% during the 1st quarter. Victory Capital Management Inc. now owns 813,140 shares of the biopharmaceutical company's stock valued at $49,236,000 after acquiring an additional 693,782 shares during the period. 96.97% of the stock is owned by hedge funds and other institutional investors.
Incyte Stock Performance
Shares of INCY stock opened at $89.31 on Friday. The company has a 50 day moving average price of $85.56 and a 200-day moving average price of $73.19. Incyte Corporation has a 52 week low of $53.56 and a 52 week high of $92.86. The firm has a market capitalization of $17.44 billion, a PE ratio of 20.30, a P/E/G ratio of 0.69 and a beta of 0.73. The company has a quick ratio of 2.78, a current ratio of 2.85 and a debt-to-equity ratio of 0.01.
Analyst Ratings Changes
A number of research firms have weighed in on INCY. Citigroup raised their price objective on shares of Incyte from $88.00 to $103.00 and gave the company a "buy" rating in a research note on Wednesday, July 30th. Zacks Research upgraded shares of Incyte from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 10th. BMO Capital Markets restated an "underperform" rating and set a $60.00 price objective (up from $52.00) on shares of Incyte in a research note on Wednesday, July 30th. UBS Group restated a "neutral" rating and set a $68.00 price objective (up from $62.00) on shares of Incyte in a research note on Wednesday, July 30th. Finally, Wall Street Zen lowered shares of Incyte from a "strong-buy" rating to a "buy" rating in a research note on Saturday, October 18th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $84.79.
Read Our Latest Analysis on INCY
Incyte Profile
(
Free Report)
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Incyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.
While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
